Abstract：Objective To investigate the effect of Paclitaxel Liposome combined with Carboplatin in the treatment of ovarian cancer. Methods A total of 60 cases of ovarian cancer treated in our hospital from January 2017 to June 2019 were selected as the resrarch objects, and they were divided into the control group and the observation group according to the random number table method, 30 cases in each group. The control group received Paclitaxel combined with Carboplatin treatment, the observation group received Paclitaxel Liposome combined with Carboplatin treatment. The short-term prognosis, side effects and quality of life at the end of treatment were compared between the two groups.Results There was no significant difference in the total effective rate between the two groups at the end of treatment(P＞0.05). The incidence of nausea, vomiting, fatigue, muscle pain and rash in the observation group were lower than those in the control group, the differences were statistically significant (P＜0.05). The scores of body function, role function, cognitive function, emotional function and social function in the observation group were higher than those in the control group, the differences were statistically significant (P＜0.05). Conclusion The efficacy of Paclitaxel Liposome is similar to that of Paclitaxel combined with Carboplatin in the treatment of ovarian cancer, but Paclitaxel Liposome has better safety and higher quality of life.
Winner KK，Steinkamp MP，Lee RJ，et al.Spatial Modeling of Drug Delivery Routes for Treatment of Disseminated Ovarian Cancer[J].Cancer Res，2016，76（6）：1320-1334.
京公网安备 11010502046607号